GTx: Enobosarm trials
GTx Inc. (GTXI) is a Memphis-based microcap biopharmaceutical company that has a large pipeline of Selective Androgen Response Modifiers (SARMs), which are androgen (male hormone) analogues. GTx has just completed two Phase III (P3) clinical trials of its lead drug, enobosarm, called POWER 1 and POWER 2. A "data lock" was placed in May, allowing the data to be analyzed. The two primary endpoints of the enobosarm POWER trials were to stabilize or improve lean body muscle (LBM) wasting (sarcopenia); and physical function (strength), in patients with advanced, Stage 3/4, non-small cell lung cancer (NSCLC). Muscle loss occurs very early in the cancer process, and, in fact, it is broken down preferentially over fat,...
Only subscribers can access this article, which is part of the PRO research library covering 3,570 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: